Boundless Bio, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of attorney (included on signature page)
POWER OF ATTORNEY AND SIGNATURES
Each person whose individual signature appears below hereby authorizes and appoints Zachary D. Hornby and David Hinkle, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Zachary D. Hornby | President and Chief Executive Officer | March 9, 2026 |
| Zachary D. Hornby | (Principal Executive Officer) | |
| /s/ David Hinkle | Senior Vice President, Finance, Controller and Treasurer | March 9, 2026 |
| David Hinkle | (Principal Financial and Accounting Officer) | |
| /s/ Jonathan E. Lim | Chairman | March 9, 2026 |
| Jonathan E. Lim, M.D. | ||
| /s/ Kristina Burow | Director | March 9, 2026 |
| Kristina Burow | ||
| /s/ James Christensen | Director | March 9, 2026 |
| James Christensen, Ph.D. | ||
| /s/ Jennifer Lew | Director | March 9, 2026 |
| Jennifer Lew | ||
| /s/ Nancy Whiting | Director | March 9, 2026 |
| Nancy Whiting, Pharm.D | ||
INDEX TO FINANCIAL STATEMENTS
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Balance Sheets as of December 31, 2025 and 2024 | F-3 |
| Statements of Operations and Comprehensive Loss for the Years ended December 31, 2025 and 2024 | F-4 |
| Statements of Convertible Preferred Stock and Stockholders’ Equity for the Years ended December 31, 2025 and 2024 | F-5 |
| Statements of Cash Flows for the Years ended December 31, 2025 and 2024 | F-6 |
| Notes to Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.